ロード中...
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
PURPOSE: AZD7762 is a Chk1 kinase inhibitor which increases sensitivity to DNA-damaging agents, including gemcitabine. We evaluated the safety of AZD7762 monotherapy and with gemcitabine in advanced solid tumor patients. EXPERIMENTAL DESIGN: In this Phase I study, patients received intravenous AZD77...
保存先:
| 出版年: | Cancer Chemother Pharmacol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4486055/ https://ncbi.nlm.nih.gov/pubmed/24448638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2380-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|